Top Page
Recordati Industria Chimica e Farmaceutica SPA
(REC)
Recordati Industria Chimica e Farmaceutica SPA (REC) vs. iShares MSCI Italy ETF (EWI)
Recordati Industria Chimica e Farmaceutica SPA Business Overview & Revenue Model
Recordati Industria Chimica e Farmaceutica SPA Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.48B | 2.34B | 2.08B | 1.85B | 1.58B | 1.45B |
| Gross Profit | 1.68B | 1.60B | 1.42B | 1.29B | 1.15B | 1.04B |
| EBITDA | 818.90M | 795.37M | 708.16M | 559.35M | 578.35M | 566.83M |
| Net Income | 407.26M | 416.51M | 389.21M | 312.34M | 385.97M | 354.98M |
Balance Sheet | ||||||
| Total Assets | 5.18B | 5.13B | 4.21B | 4.00B | 2.82B | 2.71B |
| Cash, Cash Equivalents and Short-Term Investments | 341.55M | 322.42M | 221.81M | 284.73M | 244.58M | 188.23M |
| Total Debt | 80.88M | 2.49B | 1.81B | 1.72B | 992.19M | 1.06B |
| Total Liabilities | 3.31B | 3.26B | 2.52B | 2.45B | 1.43B | 1.44B |
| Stockholders Equity | 1.87B | 1.88B | 1.69B | 1.55B | 1.38B | 1.28B |
Cash Flow | ||||||
| Free Cash Flow | 500.19M | 535.10M | 102.06M | 365.35M | 404.29M | 271.90M |
| Operating Cash Flow | 574.93M | 569.92M | 485.32M | 461.69M | 491.65M | 403.57M |
| Investing Cash Flow | -868.25M | -844.94M | -379.62M | -767.12M | -87.50M | -131.56M |
| Financing Cash Flow | 443.15M | 372.11M | -168.91M | 341.28M | -355.94M | -264.29M |
Recordati Industria Chimica e Farmaceutica SPA Technical Analysis
Recordati Industria Chimica e Farmaceutica SPA Peers Comparison
Recordati Industria Chimica e Farmaceutica SPA Corporate Events
Recordati S.p.A. has provided an update on its share buyback program, initiated to support stock options and performance share plans for its management. Between October 13 and October 17, 2025, the company purchased 56,725 of its own shares, bringing its total holdings to 4,597,656 shares, which is 2.199% of its share capital. This strategic move is likely to enhance stakeholder value and align management incentives with company performance.
The most recent analyst rating on (IT:REC) stock is a Sell with a EUR50.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. has provided an update on its share buyback program, which was initiated to support stock option and performance share plans for the company’s management. As of October 10, 2025, Recordati has purchased 20,895 shares, holding a total of 4,547,996 own shares, representing 2.175% of its share capital. This move is part of Recordati’s strategy to incentivize management and align their interests with those of shareholders, potentially impacting the company’s market positioning and stakeholder relations.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR58.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. announced an update on its share buyback program, initiated on April 30, 2025, to support stock option and performance share plans. The company purchased 28,096 ordinary shares between September 29 and October 3, 2025, at an average price of €51.0925 per share. As of October 3, 2025, Recordati held 4,552,651 own shares, representing 2.177% of its share capital. This buyback program is part of Recordati’s strategy to enhance shareholder value and support its incentive plans, reflecting its commitment to long-term growth and stability.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR58.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. has announced an update on its share buyback program, which began on April 30, 2025, following a resolution from the Shareholders’ Meeting. The program, executed by UBS Europe SE, aims to purchase shares for stock option and performance share plans. Between September 22 and 26, 2025, Recordati purchased 196,951 ordinary shares, bringing its total holdings to 4,532,555 shares, equivalent to 2.167% of its share capital. This strategic move is part of Recordati’s efforts to enhance its incentive plans and align with its growth objectives.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR56.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati has provided an update on its share buyback program, initiated on 30 April 2025, which aims to purchase shares for stock option and performance share plans. From 15 to 19 September 2025, Recordati purchased 108,016 ordinary shares, with a weighted average price of €53.1151 per share, bringing its total holdings to 4,342,104 shares, or 2.076% of the share capital. This move is part of Recordati’s strategy to enhance its financial structure and incentivize management, potentially impacting its market positioning positively.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR57.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. announced the resignation of Dr. Luigi La Corte from his role as Group CFO, effective at the end of the year, while he will continue to serve on the Board of Directors. The company is considering both internal and external candidates for the CFO position and will announce a successor in due course. The resignation is accompanied by a financial package and retention of certain stock options for Dr. La Corte. Additionally, the Board confirmed the independence of Dr. Silvia Mina as a Statutory Auditor, following the resignation of Dr. Livia Amidani Aliberti.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR57.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. has announced an update on its share buyback program, which commenced on April 30, 2025. The program aims to purchase shares for stock option and performance share plans for the management of the Recordati Group. Between September 8 and September 12, 2025, the company purchased a total of 63,869 shares at a weighted average price of €54.0053 per share. As of September 12, 2025, Recordati holds 4,234,088 own shares, representing 2.025% of its share capital. This strategic move is expected to support the company’s incentive plans and potentially enhance shareholder value.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR57.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. has provided an update on its share buyback program, which began on 30 April 2025, following a resolution from the Shareholders’ Meeting. The program aims to purchase shares for stock option and performance share plans for the management of the Recordati Group. From 1 to 5 September 2025, the company purchased a total of 40,549 shares at an average price of 53.4694 euros per share. As of 5 September 2025, Recordati held 4,204,802 own shares, representing 2.011% of its share capital. This strategic move is part of Recordati’s efforts to enhance its market positioning and provide incentives to its management team.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR57.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. has updated its shareholders on the progress of its share buyback program, which began on 30 April 2025. The company executed several purchase operations between 25 and 29 August 2025, acquiring a total of 54,614 shares at an average price of 52.6377 Euros per share. This initiative is part of Recordati’s strategy to service stock options and performance share plans for its management, enhancing its incentive plans and potentially impacting its market position.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR57.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. has provided an update on its share buyback program, which began on April 30, 2025, following a resolution by the Shareholders’ Meeting. The program aims to purchase shares for stock options and performance share plans for the company’s management. Between August 18 and 22, 2025, Recordati purchased 38,121 ordinary shares at an average price of 52.1938 Euros per share. As of August 22, 2025, Recordati holds 4,149,013 own shares, representing 1.984% of its share capital.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR57.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. has announced an update on its share buyback program, initiated on April 30, 2025, to support stock option and performance share plans for its management. Between August 11 and 15, 2025, the company purchased a total of 40,307 ordinary shares at a weighted average price of €50.5448 per share. As of August 15, 2025, Recordati holds 4,112,354 own shares, representing 1.966% of its share capital. This strategic move is expected to enhance the company’s operational flexibility and align management incentives with shareholder interests.
The most recent analyst rating on (IT:REC) stock is a Buy with a EUR61.50 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. has provided an update on its share buyback program, initiated on April 30, 2025, to support stock options and performance share plans for its management. The company reported purchasing 114,072 ordinary shares between August 4 and August 8, 2025, at a weighted average price of 50.3567 Euros per share, holding 1.951% of its share capital as of August 8, 2025. This move is part of Recordati’s strategic efforts to enhance shareholder value and align management incentives with company performance.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. has updated its share buyback program, initially communicated in April 2025, with recent transactions executed by UBS Europe SE. From July 28 to August 1, 2025, the company purchased a total of 176,283 shares at a weighted average price of 51.7557 Euros per share. As of August 1, 2025, Recordati holds 3,965,975 own shares, representing 1.896% of its share capital. This buyback is part of Recordati’s strategy to allocate shares for stock option and performance share plans aimed at management incentives.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. announced the resignation of Dr. Livia Amidani Aliberti as Actual Auditor, effective immediately, due to personal reasons. Dr. Silvia Mina, previously an Alternate Auditor, will assume the role of Actual Auditor until the next Shareholders’ Meeting. This change is in accordance with the company’s Articles of Association and does not impact the company’s shareholding structure as neither auditor holds shares in the company.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati has published its half-year financial report as of June 30, 2025, which has been approved by the Board of Directors and is now accessible to the public. This announcement underscores Recordati’s commitment to transparency and its strategic positioning in the pharmaceutical industry, potentially impacting stakeholders by providing insights into the company’s financial health and operational progress.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. has updated its shareholders on the execution of its share buyback program, initiated to support stock option and performance share plans for its management. The company purchased a total of 52,802 ordinary shares between July 21 and July 25, 2025, with an average price of €52.5805 per share. As of July 25, 2025, Recordati holds 3,815,712 own shares, representing 1.825% of its share capital.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati reported strong financial performance in the first half of 2025, with consolidated net revenues increasing by 11.7% to €1,323.8 million. The company signed a license and supply agreement with Amarin for the commercialization of Vazkepa® in Europe, enhancing its cardiovascular portfolio. Despite adverse exchange rate impacts, Recordati maintained its financial targets for 2025, demonstrating robust execution and strategic growth in both its Specialty & Primary Care and Rare Diseases sectors.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
Recordati S.p.A. announced an update on its share buyback program, which began on 30 April 2025. The program aims to purchase shares to support stock options and performance share plans for the management of the Recordati Group. From 14 to 18 July 2025, Recordati purchased 130,231 ordinary shares at an average price of €52.9464 per share. As of 18 July 2025, the company held 3,764,910 own shares, representing 1.800% of its share capital. This move is part of Recordati’s strategy to enhance shareholder value and support its incentive plans.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.